Literature DB >> 9644626

Renal endothelin system in polycystic kidney disease.

B Hocher1, R Zart, A Schwarz, V Vogt, C Braun, C Thöne-Reineke, N Braun, H H Neumayer, K Koppenhagen, C Bauer, P Rohmeiss.   

Abstract

Polycystic kidney disease (PKD) is characterized by interstitial fibrosis and formation of renal cysts. Interestingly, interstitial fibrosis and renal cyst formation were also seen in human endothelin-1 (ET-1) transgenic mice. This study, therefore, analyzes the tissue distribution of ET-1, the tissue concentrations of ET-1, as well as the expression of ET receptor subtypes in the kidneys of a rat model of PKD: Han:SPRD rats. Six-week-old heterozygous (cy/+) and homozygous (cy/cy), as well as 6-mo-old heterozygous (cy/+) Han:SPRD rats and the corresponding age-matched Sprague Dawley littermates (SD) (+/+) were analyzed. Furthermore, the acute effects of the mixed (A/B) endothelin receptor antagonist bosentan on hemodynamic and renal function were investigated in 6-mo-old, conscious, chronically instrumented (cy/+) rats. The kidneys of affected rats showed significantly elevated tissue levels of ET-1 compared with age-matched controls (3.5 +/- 0.3-fold in young cy/cy rats, P < 0.01; 1.4 +/- 0.2-fold in young cy/+ rats, P < 0.01; 6.2 +/- 0.4-fold in old cy/+ rats, P < 0.001) due to a highly increased ET-1 synthesis within the epithelial cells of the cysts. Analyzing tissue sections from patients with typical autosomal dominant PKD demonstrated a high ET-1 expression within the epithelial cells of the cysts as well. Scatchard analysis revealed a markedly decreased ETA and ETB receptor density in all groups of affected rats. The acute blockade of both endothelin receptor subtypes using bosentan in 6-mo-old heterozygous PKD rats led to a significant decrease in mean arterial BP (MAP) (-19.7 +/- 2.1 mmHg, P < 0.05) and GFR (-41 +/- 5%, P < 0.005). Renal blood flow (RBF) was significantly increased (+2.1 +/- 0.5 ml/min, P < 0.05) after bosentan, whereas bosentan had no effect on MAP, GFR, and RBF in age-matched controls. These data show that the paracrine renal endothelin system is activated in PKD and participates in the regulation of MAP, GFR, RBF, and possibly contributes to renal cyst formation and fibrosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9644626     DOI: 10.1681/ASN.V971169

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  13 in total

Review 1.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.

Authors:  Yunxia Tao; Jun Kim; Sarah Faubel; Joe C Wu; Sandor A Falk; Robert W Schrier; Charles L Edelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-29       Impact factor: 11.205

3.  The association of endothelin-1 levels with renal survival in polycystic kidney disease patients.

Authors:  Ismail Kocyigit; Eray Eroglu; Ahmet Safa Kaynar; Derya Kocer; Seval Kargi; Gokmen Zararsiz; Ruslan Bayramov; Hakan Imamoglu; Murat Hayri Sipahioglu; Bulent Tokgoz; Munis Dundar; Oktay Oymak
Journal:  J Nephrol       Date:  2018-07-18       Impact factor: 3.902

Review 4.  Angiogenesis and autosomal dominant polycystic kidney disease.

Authors:  Jennifer L Huang; Adrian S Woolf; David A Long
Journal:  Pediatr Nephrol       Date:  2012-09-19       Impact factor: 3.714

Review 5.  Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.

Authors:  Markus P Schneider; Erika I Boesen; David M Pollock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 6.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

7.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

8.  Cell-type specific interaction of endothelin and the nitric oxide system: pattern of prepro-ET-1 expression in kidneys of L-NAME treated prepro-ET-1 promoter-lacZ-transgenic mice.

Authors:  Torsten Slowinski; Philipp Kalk; Maren Christian; Fred Schmager; Katharina Relle; Michael Godes; Heiko Funke-Kaiser; Hans-H Neumayer; Christian Bauer; Franz Theuring; Berthold Hocher
Journal:  J Physiol       Date:  2007-03-29       Impact factor: 5.182

Review 9.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

10.  Deficiency in Six2 during prenatal development is associated with reduced nephron number, chronic renal failure, and hypertension in Br/+ adult mice.

Authors:  Ben Fogelgren; Shiming Yang; Ian C Sharp; Odaro J Huckstep; Wenbin Ma; S J Somponpun; Edward C Carlson; Catherine F T Uyehara; Scott Lozanoff
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.